Boule Diagnostics AB (publ) (BOUL.ST)
SEK 8.84
(-1.56%)
SEK 8.84
(-1.56%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 571.32 Million SEK | 4.24% |
| 2022 | 548.08 Million SEK | 18.29% |
| 2021 | 463.34 Million SEK | 15.7% |
| 2020 | 400.45 Million SEK | -19.73% |
| 2019 | 498.91 Million SEK | 17.56% |
| 2018 | 424.4 Million SEK | -0.79% |
| 2017 | 427.79 Million SEK | 6.75% |
| 2016 | 400.73 Million SEK | 20.92% |
| 2015 | 331.4 Million SEK | 8.06% |
| 2014 | 306.68 Million SEK | 10.8% |
| 2013 | 276.8 Million SEK | 0.55% |
| 2012 | 275.3 Million SEK | 11.84% |
| 2011 | 246.15 Million SEK | 7.29% |
| 2010 | 229.42 Million SEK | 30.81% |
| 2009 | 175.39 Million SEK | 3.97% |
| 2008 | 168.69 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 147.8 Million SEK | -0.2% |
| 2024 Q3 | 130.5 Million SEK | -4.74% |
| 2024 Q2 | 137 Million SEK | -7.31% |
| 2023 Q3 | 139.7 Million SEK | -0.57% |
| 2023 Q4 | 148.1 Million SEK | 6.01% |
| 2023 FY | 571.3 Million SEK | 4.24% |
| 2023 Q1 | 143.1 Million SEK | -4.15% |
| 2023 Q2 | 140.5 Million SEK | -1.82% |
| 2022 Q1 | 132.5 Million SEK | -5.59% |
| 2022 Q3 | 125.6 Million SEK | -10.8% |
| 2022 FY | 548.08 Million SEK | 18.29% |
| 2022 Q4 | 149.28 Million SEK | 18.86% |
| 2022 Q2 | 140.8 Million SEK | 6.26% |
| 2021 Q3 | 111.8 Million SEK | 0.99% |
| 2021 Q2 | 110.7 Million SEK | 10.04% |
| 2021 Q4 | 140.34 Million SEK | 25.53% |
| 2021 FY | 463.34 Million SEK | 15.7% |
| 2021 Q1 | 100.6 Million SEK | 8.57% |
| 2020 Q4 | 92.65 Million SEK | -6.22% |
| 2020 Q1 | 118.4 Million SEK | -0.52% |
| 2020 Q2 | 90.6 Million SEK | -23.48% |
| 2020 FY | 400.45 Million SEK | -19.73% |
| 2020 Q3 | 98.8 Million SEK | 9.05% |
| 2019 Q3 | 135.3 Million SEK | 13.03% |
| 2019 Q4 | 119.01 Million SEK | -12.04% |
| 2019 Q1 | 118.6 Million SEK | 11.68% |
| 2019 FY | 498.91 Million SEK | 17.56% |
| 2019 Q2 | 119.7 Million SEK | 0.93% |
| 2018 Q4 | 106.2 Million SEK | -4.24% |
| 2018 FY | 424.4 Million SEK | -0.79% |
| 2018 Q3 | 110.9 Million SEK | 2.88% |
| 2018 Q2 | 107.8 Million SEK | 8.34% |
| 2018 Q1 | 99.5 Million SEK | -7.26% |
| 2017 Q2 | 104.3 Million SEK | -2.16% |
| 2017 Q1 | 106.6 Million SEK | 0.72% |
| 2017 Q3 | 109.7 Million SEK | 5.18% |
| 2017 Q4 | 107.29 Million SEK | -2.19% |
| 2017 FY | 427.79 Million SEK | 6.75% |
| 2016 Q2 | 102 Million SEK | 20.85% |
| 2016 Q3 | 108.5 Million SEK | 6.37% |
| 2016 Q4 | 105.83 Million SEK | -2.46% |
| 2016 Q1 | 84.4 Million SEK | -4.53% |
| 2016 FY | 400.73 Million SEK | 20.92% |
| 2015 Q3 | 88.8 Million SEK | 12.55% |
| 2015 Q1 | 75.3 Million SEK | -16.41% |
| 2015 Q4 | 88.4 Million SEK | -0.44% |
| 2015 Q2 | 78.9 Million SEK | 4.78% |
| 2015 FY | 331.4 Million SEK | 8.06% |
| 2014 Q2 | 69.7 Million SEK | -4.91% |
| 2014 Q4 | 90.08 Million SEK | 22.4% |
| 2014 FY | 306.68 Million SEK | 10.8% |
| 2014 Q1 | 73.3 Million SEK | 1.5% |
| 2014 Q3 | 73.6 Million SEK | 5.6% |
| 2013 FY | 276.8 Million SEK | 0.55% |
| 2013 Q2 | 71.25 Million SEK | 12.32% |
| 2013 Q4 | 72.21 Million SEK | 3.32% |
| 2013 Q3 | 69.89 Million SEK | -1.91% |
| 2013 Q1 | 63.44 Million SEK | -16.89% |
| 2012 Q2 | 70.96 Million SEK | 10.44% |
| 2012 Q4 | 76.33 Million SEK | 19.74% |
| 2012 Q1 | 64.25 Million SEK | -5.05% |
| 2012 FY | 275.3 Million SEK | 11.84% |
| 2012 Q3 | 63.75 Million SEK | -10.16% |
| 2011 Q4 | 67.67 Million SEK | 17.3% |
| 2011 Q2 | 57.55 Million SEK | -9.0% |
| 2011 Q1 | 63.24 Million SEK | -5.54% |
| 2011 FY | 246.15 Million SEK | 7.29% |
| 2011 Q3 | 57.68 Million SEK | 0.24% |
| 2010 Q4 | 66.95 Million SEK | 21.48% |
| 2010 FY | 229.42 Million SEK | 30.81% |
| 2010 Q1 | 47.91 Million SEK | 0.0% |
| 2010 Q3 | 55.11 Million SEK | -7.26% |
| 2010 Q2 | 59.43 Million SEK | 24.03% |
| 2009 FY | 175.39 Million SEK | 3.97% |
| 2008 FY | 168.69 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Acarix AB (publ) | 6.24 Million SEK | -9054.446% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 58.388% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 58.388% |
| Arcoma AB | 163.01 Million SEK | -250.476% |
| Bactiguard Holding AB (publ) | 203.99 Million SEK | -180.077% |
| BICO Group AB (publ) | 2.23 Billion SEK | 74.489% |
| CellaVision AB (publ) | 677.29 Million SEK | 15.645% |
| Clinical Laserthermia Systems AB (publ) | 8.27 Million SEK | -6805.947% |
| Chordate Medical Holding AB (publ) | 976.28 Thousand SEK | -58420.959% |
| C-Rad AB (publ) | 424.61 Million SEK | -34.552% |
| Duearity AB (publ) | 1.65 Million SEK | -34442.261% |
| Dignitana AB (publ) | 86.06 Million SEK | -563.85% |
| Episurf Medical AB (publ) | 10.3 Million SEK | -5446.883% |
| Getinge AB (publ) | 31.82 Billion SEK | 98.205% |
| Scandinavian Real Heart AB (Publ) | - SEK | -Infinity% |
| Iconovo AB (publ) | 7.07 Million SEK | -7971.57% |
| Integrum AB (publ) | 104.11 Million SEK | -448.729% |
| Luxbright AB (publ) | 854.69 Thousand SEK | -66745.638% |
| Mentice AB (publ) | 273.61 Million SEK | -108.811% |
| OssDsign AB (publ) | 112.15 Million SEK | -409.401% |
| Paxman AB (publ) | 210.11 Million SEK | -171.91% |
| Promimic AB (publ) | 37.07 Million SEK | -1441.217% |
| Qlife Holding AB (publ) | 244 Thousand SEK | -234051.23% |
| SciBase Holding AB (publ) | 23.24 Million SEK | -2357.858% |
| ScandiDos AB (publ) | 60.42 Million SEK | -845.455% |
| Sectra AB (publ) | 2.96 Billion SEK | 80.722% |
| Sedana Medical AB (publ) | 153.86 Million SEK | -271.314% |
| Senzime AB (publ) | 35.75 Million SEK | -1497.944% |
| SpectraCure AB (publ) | 318 Thousand SEK | -179563.208% |
| Stille AB | 294.89 Million SEK | -93.741% |
| Vitrolife AB (publ) | 3.51 Billion SEK | 83.732% |
| Xvivo Perfusion AB (publ) | 597.54 Million SEK | 4.387% |